Effective Dexmedetomidine Dose for Stage N2 Sleep Induction and Associated Factors in Depression-Related Insomnia: A Polysomnography-Based Analysis
Rattachement africain : cn, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: -adrenergic receptor agonist, shows unique advantages in inducing sleep closely resembling physiological sleep and is gaining interest as a potential therapy for insomnia. Objective: This study aimed to determine the average effective Dex dose for inducing stage N2 sleep in patients with depression-related insomnia via polysomnography (PSG), and to identify factors affecting dose variability. Methods: From April to August 2023, 91 patients with depression-related insomnia were recruited from the Center for Pain and Sleep Medicine at the Affiliated Hospital of Shandong Second Medical University. All patients received intravenous Dex infusion (diluted to 4 μg/mL and administered at 60 mL/h) under continuous PSG monitoring. The cumulative Dex dose required to induce stage N2 sleep was recorded. Clinical data were collected, and univariate and multiple linear regression analyses were performed to identify factors influencing Dex dose. Results: = 0.181). During titration, patients' vital signs remained stable, with heart rate significantly decreasing (68.2 ± 10.0 vs 57.0 ± 13.3 bpm, P < 0.05), whereas mean arterial pressure and oxygen saturation showed no significant changes (P > 0.05). Conclusion: Dex could effectively induces stage N2 sleep in patients with depression-related insomnia and has a favorable safety profile, with the required dose increasing with age.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Effective Dexmedetomidine Dose for Stage N2 Sleep Induction and Associated Factors in Depression-Related Insomnia: A Polysomnography-Based Analysis
- Date Crossref
- 01/09/2025
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Weifang Medical University Center for Pain & Sleep Medicine pays non établi dans la noticeUniversité ou école supérieure
-
TCM-Intigrated Cancer Center of Southern Medical University Brain Disease Institute & Department of Anesthesiology for the Integrated Traditional Chinese and Western Medicine Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Chinese Academy of Sciences Medical School pays non établi dans la noticeUniversité ou école supérieure
-
University of Pittsburgh Department of Anesthesiology pays non établi dans la noticeUniversité ou école supérieure
Center for Pain & Sleep Medicine — Weifang Medical University, Brain Disease Institute & Department of Anesthesiology for the Integrated Traditional Chinese and Western Medicine Hospital — TCM-Intigrated Cancer Center of Southern Medical University et Medical School — University of Chinese Academy of Sciences, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.